Sanofi has posted results of a 24-week Phase IIIb clinical study of Lyxumia (lixisenatide). The trial met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or the main meal of the day. These results indicate that lixisenatide can effectively lower blood sugar at either time of administration. The results also showed that a comparable reduction in body weight, regardless of the meal before which lixisenatide was administered, was ac...